| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Third Point · Dan Loeb | $8.0M | 0.17% | 1.00M | — | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SPRY trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jun 11, 2026 | Karas EricOfficer | Conversion of Exercise of derivative security at price 1.50 per share. | 25K | $37.50K |
| Jun 11, 2026 | Fitzpatrick Alexander A.Officer | Sale at price 10.00 per share. | 3.4K | $33.55K |
| Jun 11, 2026 | Karas EricOfficer | Sale at price 10.00 per share. | 25K | $250.00K |
| Nov 12, 2025 | Dorsey Brian TChief Operating Officer | Conversion of Exercise of derivative security at price 0.64 per share. | 21.8K | $13.97K |
| Nov 12, 2025 | Dorsey Brian TChief Operating Officer | Sale at price 8.71 per share. | 21.8K | $190.05K |
| Nov 11, 2025 | Shah PratikDirector | Stock Gift at price 0.00 per share. | 350K | — |
| Nov 11, 2025 | Chakma JustinOfficer | Conversion of Exercise of derivative security at price 0.84 per share. | 30K | $25.20K |
| Nov 11, 2025 | Chakma JustinOfficer | Sale at price 8.86 - 8.91 per share. | 166.4K | $1.48M |
| Aug 20, 2025 | Scott Kathleen DChief Financial Officer | Conversion of Exercise of derivative security at price 1.50 per share. | 12.5K | $18.75K |
| Aug 20, 2025 | Lowenthal Richard EChief Executive Officer | Sale at price 14.49 per share. | 50K | $724.35K |
| Aug 20, 2025 | Scott Kathleen DChief Financial Officer | Sale at price 15.00 per share. | 12.5K | $187.50K |
| Aug 19, 2025 | Tanimoto SarinaOfficer and Beneficial Owner of more than 10% of a Class of Security | Sale at price 14.03 - 14.09 per share. | 50K | $703.75K |
| Jun 30, 2025 | Karas EricOfficer | Conversion of Exercise of derivative security at price 1.50 per share. | 15K | $22.50K |
| Jun 30, 2025 | Karas EricOfficer | Sale at price 16.99 per share. | 15K | $254.86K |
| Jun 26, 2025 | Flynn James EBeneficial Owner of more than 10% of a Class of Security | Sale at price 18.46 per share. | 740.1K | $13.66M |
| Jun 17, 2025 | Karas EricOfficer | Conversion of Exercise of derivative security at price 1.50 per share. | 15K | $22.50K |
| Jun 17, 2025 | Karas EricOfficer | Sale at price 16.00 per share. | 15K | $240.00K |
| May 19, 2025 | Saunders Brent L.Director | Conversion of Exercise of derivative security at price 1.01 per share. | 120K | $121.20K |
| May 19, 2025 | Fitzpatrick Alexander A.Officer | Conversion of Exercise of derivative security at price 5.58 per share. | 100K | $558.00K |
| May 19, 2025 | Scott Kathleen DChief Financial Officer | Conversion of Exercise of derivative security at price 1.50 per share. | 50K | $75.00K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.2 | -7.1 | -13.5 | 2.9 | 9.8 | -11.7 | -36.0 | 17.0 | -28.2 | -5.8 | −65.2% | ||
| 2025 | 23.4 | -19.5 | 20.0 | 11.0 | 3.3 | 20.9 | 1.3 | -34.3 | -13.5 | -10.8 | 6.5 | 22.1 | +10.4% |
| 2024 | 13.3 | 34.8 | 22.1 | -14.9 | 2.1 | -4.2 | 27.7 | 19.4 | 11.7 | 1.5 | -1.4 | -27.3 | +92.5% |
| 2023 | -19.6 | 30.0 | -27.0 | -0.2 | 7.1 | -3.7 | 9.7 | -3.5 | -46.7 | -5.6 | 35.3 | 13.5 | −35.8% |
| 2022 | -26.9 | -11.7 | -18.4 | -11.4 | 12.2 | 21.5 | 21.7 | 5.4 | -2.9 | 17.8 | 0.0 | 37.1 | +28.1% |
| 2021 | -5.2 | 9.4 | -9.2 | -26.5 | -14.1 | 12.2 | -2.0 | -27.3 | -54.6 | -13.5 | -18.5 | -5.3 | −85.6% |
| 2020 | — |
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Buy / hold / sell counts